WO2003026619A1 - Granules presentant des proprietes de dosage ameliorees - Google Patents

Granules presentant des proprietes de dosage ameliorees Download PDF

Info

Publication number
WO2003026619A1
WO2003026619A1 PCT/JP2002/009910 JP0209910W WO03026619A1 WO 2003026619 A1 WO2003026619 A1 WO 2003026619A1 JP 0209910 W JP0209910 W JP 0209910W WO 03026619 A1 WO03026619 A1 WO 03026619A1
Authority
WO
WIPO (PCT)
Prior art keywords
water
drugs
component
saliva
added
Prior art date
Application number
PCT/JP2002/009910
Other languages
English (en)
Japanese (ja)
Inventor
Kouji Murai
Akihiro Uchida
Masaharu Aimoto
Yasuki Kato
Original Assignee
Kyowa Hakko Kogyo Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co., Ltd. filed Critical Kyowa Hakko Kogyo Co., Ltd.
Priority to JP2003530256A priority Critical patent/JPWO2003026619A1/ja
Publication of WO2003026619A1 publication Critical patent/WO2003026619A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Definitions

  • the present invention relates to granules having improved ingestibility.
  • granules are widely used as highly versatile dosage forms, and are especially useful when the swallowing ability is low and it is difficult to take tablets and other molded products, such as elderly people and children. Even for adults, granules are easier to take than other dosage forms when the dose is increased. In addition, granules have the advantage that the dosage can be adjusted accurately depending on the disease state and age, and are suitable for preparation.
  • Granules containing active ingredients or excipients that are sparingly soluble in water or saliva, or active ingredients that become sparingly soluble in water or saliva by coating or matrixing the active ingredient with a coating material are likely to produce a rough feeling due to the feeling of the hardness of the particles in the oral cavity, greatly reducing the ingestibility.
  • rapidly disintegrating tablets in the oral cavity which are a form of molded preparations such as tablets, are tablets that dissolve or disintegrate quickly in the oral cavity after being taken, and can be easily taken by elderly people and children.
  • Kaihei 5-271054, JP-A-8-291051 Similarly, oral rapidly disintegrating granules that dissolve or disintegrate rapidly in the oral cavity after ingestion are also known (JP-A-11-343231, Patent No. 3018318).
  • the active ingredient or excipient or the active ingredient that is hardly soluble in water or saliva is one or two selected from the group consisting of acryl polymers, cellulose polymers, natural polymers, oils and fats, and oil salts.
  • An object of the present invention is to eliminate the graininess caused by feeling the scattering in the oral cavity and the hardness of the particles when a granule containing a component that is hardly soluble in water or saliva is taken. To improve the ingestibility of the drug.
  • the present invention relates to the following (1) to (40).
  • a feeling of roughness in the oral cavity when ingested characterized by containing a component that is hardly soluble in water or saliva and a component that becomes a viscous liquid when water is added. Granules with reduced content.
  • a component that is hardly soluble in water or saliva, and the active ingredient is coated with one or more coating agents selected from the group consisting of acrylic polymers, cellulose polymers, natural polymers, oils and fats and oils and salts.
  • the granule according to the above (1) which is a matrixed active ingredient.
  • Insoluble components in water or saliva are active nervous system drugs, somatic nervous system drugs, smooth muscle drugs, antihistamines ⁇ ⁇ ⁇ ⁇ ⁇ allergic drugs, central nervous system drugs, cardiovascular system Agonists, Diuretics, Antidiuretics, Respiratory drugs, Gastrointestinal drugs, Blood and hematopoietic organ drugs, Hormones, Vitamins, Antidotes, Antiinfectives, Antineoplastic drugs, Immunological drugs, The granule according to the above (1), which is one or more active ingredients selected from the group consisting of diagnostic agents and narcotics' stimulants.
  • Insoluble ingredients in water or saliva acetilsviramycin, amoxicillin, ethyl icosapentate, traconazole, oxatomide, gribuzole, gluyuthione, ketofenylbuzozon, copamamid, cisapuri , Todolalazine hydrochloride, tropisetron hydrochloride, domperidone, sodium valproate, fluorouracil, flunarizine hydrochloride, flurazepam hydrochloride, benidipine hydrochloride, minocycline hydrochloride, mebendazol, medroxyprogesterone, ubidecarenone, pyridoxalone and pyridoxal phosphate
  • the granule according to the above (1) which is one or more active ingredients selected from the group consisting of Lepodova.
  • the components that become a viscous liquid when water is added are hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, polyvinyl alcohol, polyethylene oxide, pullulan, sodium alginate, gelatin, agar, and copolydon.
  • the granules according to any one of (1) to (5).
  • Oxatomide is a component that is hardly soluble in water or saliva, and a component that becomes a viscous liquid when water is added is hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxypropyl starch.
  • the granule according to the above (1) which is two or more kinds selected from the group consisting of:
  • the agent for improving the ingestibility of granules according to the above (11) or (12), wherein the components that become a viscous liquid when water is added are a binder and Z or a disintegrant.
  • a component which is hardly soluble in water or saliva is coated with one or more coating agents selected from the group consisting of acrylyl polymer, cellulose polymer, natural polymer, fats and oils and fats or salts.
  • Insoluble or soluble components in water or saliva autonomic nervous system drugs, somatic nerve system drugs, smooth muscle drugs, antihistamines, allergy drugs, central nervous system drugs, cardiovascular system Agonists, diuretics 'Antidiuretics, Respiratory drugs, Gastrointestinal drugs, Blood' Hematopoietic organ drugs, hormones, vitamins, antidote drugs, anti-infective drugs, anti-neoplastic drugs, immunological drugs, The agent for reducing sensation of roughness described in the above (14), which is one or more active ingredients selected from the group consisting of a diagnostic drug and a drug and a stimulant.
  • Insoluble components in water or saliva include acetilsviramycin, amoxicillin, ethyl ethyl icosapentate, itraconazole, oxatomid, Gribzol, Guluyethione, Ketofenilbudin, Cobamamide, Cisapride, Todolalazine hydrochloride, Tropisetron hydrochloride, Domperidone, Sodium valproate, Fluorouracil, Flunarizine hydrochloride, Flurazepam hydrochloride, Bendipine hydrochloride, Hydrochloride
  • the agent according to the above (14) which is one or more active ingredients selected from the group consisting of minocycline, mebendazole, medroxyprogesterone, ubidecarenone, pyridoxal phosphate and repodova.
  • the components that become viscous liquids when water is added are hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, polyvinyl alcohol, polyethylene oxide, pullulan, sodium alginate, gelatin, agar, and copolydon.
  • One or more binders selected from the group consisting of corn starch, potato starch, pregelatinized starch, sodium carboxymethyl starch and hydroxypropyl starch, and Z or a disintegrant ( 14) The reducer according to any one of claims 18 to 18.
  • the component that is hardly soluble in water or saliva is oxatomide, and the component that becomes a viscous liquid when water is added consists of hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxypropylstarch.
  • Poorly soluble components in water or saliva include autonomic nervous system drugs, somatic nervous system drugs, smooth muscle drugs, antihistamines, allergy drugs, central nervous system drugs, cardiovascular system Agonists, diuretics * Antidiuretics, respiratory drugs, digestive drugs, blood and hematopoietic organ drugs, hormones, vitamins, antidote drugs, anti-infective drugs, anti-neoplastic drugs, immunological drugs, (29)
  • the method according to the above (29) which is one or more active ingredients selected from the group consisting of diagnostic agents and narcotics' stimulants.
  • the component that becomes a viscous liquid when water is added is a binder and / or The method for reducing graininess according to any one of the above (29) to (33), which is a disintegrant.
  • the components that become viscous liquids when water is added are hydroxypropyl methylcellulose, hydroxypropylcellulose, methylcellulose, polyvinyl alcohol, polyethylene oxide, pullulan, sodium alginate, gelatin, agar, and copolydon. (29) to (28) to which are one or more binders and / or disintegrators selected from the group consisting of corn starch, potato starch, pregelatinized starch, carboxymethyl starch sodium and hydroxypropyl starch. (33) The method for reducing a feeling of roughness according to any one of (33).
  • the component that is hardly soluble in water or saliva is oxatomide, and the component that becomes a viscous liquid when water is added is hydroxypropylmethylcellulose, hydroxypropylcellulose, and hydroxypropyl starch.
  • (38) Contains a component that becomes a viscous liquid when water is added to a tablet that can be obtained by compression-molding a granule containing a component that is hardly soluble in water or saliva with a tableting machine. A method for reducing roughness in the oral cavity when taking the tablet.
  • the granules of the present invention contain a component that is hardly soluble in water or saliva and a component that becomes a viscous liquid when water is added.
  • the oral cavity on the tongue, sublingual, gums, maxilla, There are no particular limitations on the granules that have a reduced feeling of roughness in the throat, etc., and have improved takeability.
  • the granules include pills, granules, fine granules, and the like described in the Japanese Pharmacopoeia. Powders and the like.
  • the water- or saliva-insoluble component used in the present invention means that it is insoluble or partially soluble in the amount of water used when taking the drug, Or, those that do not dissolve or remain partially soluble in saliva in the oral cavity.
  • the component that is hardly soluble in water or saliva the active ingredient that is hardly soluble in water or saliva, water or Excipients that are hardly soluble in saliva are exemplified.
  • the active ingredient is one or two or more kinds of coating agents selected from the group consisting of acryl polymer, cellulose polymer, natural polymer, oil and fat, oil and fat salt, etc. Also included are active ingredients which are coated or matrixed to render them poorly soluble in water or saliva. At this time, there is no limitation on the solubility of the active ingredient, and depending on the characteristics of the active ingredient, the active ingredient that has become hardly soluble in water or saliva as a result of being coated or matrixed with an appropriate coating agent is used. Point.
  • coating or matrix formation examples include masking of taste and odor, enteric coating or sustained release, stabilization such as light shielding and moisture proofing, and the like, and coating or matrix formation can be performed by a known method. Above all, masking of taste and odor is preferably considered in order to improve ingestibility.
  • the coating agent used in the present invention include acrylic polymers such as copolymers of methacrylic acid, aminoalkyl methacrylate copolymers and carboxyvinyl polymers (the acrylic polymers include acrylic acid derivatives and Z Or methacrylic acid derivatives are polymerized), ethylcellulose, cellulose polymers such as hydroxypropylmethylcellulose, hydroxypropylcellulose and cellulose acetate phthalate, gum arabic, pullulan, alginic acid, agar, gelatin, etc. And one or more kinds of coating agents selected from oils and fats and oils such as stearic acid, magnesium stearate, hardened oil, paraffin, carnavalo-glycerin fatty acid ester, and the like.
  • coatings may optionally be used with plasticizers or soluble additives, for example, polyethylene glycol, polyoxyethylenepolyoxypropylene glycol, polyoxyethylene hydrogenated castor oil, triethyl citrate, It may be used by mixing with polysorbate, sugar, sugar alcohol, oligosaccharide and the like.
  • plasticizers or soluble additives for example, polyethylene glycol, polyoxyethylenepolyoxypropylene glycol, polyoxyethylene hydrogenated castor oil, triethyl citrate, It may be used by mixing with polysorbate, sugar, sugar alcohol, oligosaccharide and the like.
  • the active ingredient that is hardly soluble in water or saliva may be, for example, any of solid, powder, crystal, oil, and solution, and specific examples thereof include, for example, an autonomic nervous system drug, Somatic nervous system drug, smooth muscle drug, antihistamine, are Lugi Ichii, Central nervous system drugs, Cardiovascular drugs, Diuretics * Anti-diuretics, Respiratory drugs Ji, Gastrointestinal drugs, Blood and hematopoietic organ drugs, Hormones, Vitamin, Antidote, One or more active ingredients selected from anti-infectives, antineoplastics, immunological drugs, diagnostics, narcotics, stimulants, and the like.
  • active ingredients and the like can be mentioned.
  • Pharmaceutically acceptable salts include pharmaceutically acceptable acid addition salts, metal salts, ammonium salts, organic amine addition salts, amino acid addition salts and the like.
  • the acid addition salts include inorganic acid salts such as hydrochloride, sulfate, and phosphate, and organic acid salts such as acetate, maleate, fumarate, tartrate, citrate, and lactate.
  • the metal salt include alkali metal salts such as a lithium salt, a sodium salt, and a potassium salt; alkaline earth metal salts such as a magnesium salt and a calcium salt; an aluminum salt; a zinc salt; and the like.
  • Salts such as ammonium and tetramethylammonium; organic amine addition salts include addition salts such as morpholine and piperidine; amino acid addition salts include glycine, phenylalanine, aspartic acid, and the like. Additional salts such as glutamic acid and lysine are exemplified.
  • excipient that is hardly soluble in water or saliva is not particularly limited, and examples thereof include light anhydrous silicic acid, hydrated silicon dioxide, magnesium aluminate metasilicate, hydrotalcite, calcium carbonate, and the like.
  • the content of the active ingredient that is hardly soluble in water or saliva in the granules of the present invention is preferably 0.001% to 80%, more preferably 0.1% to 50%.
  • the content of the poorly soluble excipient is preferably 0.1% to 95%, more preferably 1% to 50%.
  • the components used in the present invention that become a viscous liquid when water is added include those that dissolve or swell when water is added, and are transparent or suspended viscous liquids or viscous liquids. It is not particularly limited as long as it becomes a liquid, but preferably, a binder which becomes a viscous liquid when water is added, a disintegrating agent which becomes a viscous liquid when water is added, and the like are preferable.
  • binders and / or disintegrators selected from the group consisting of mono-tinadium and hydroxypropyl starch. The component that becomes a viscous liquid when added to water is brought into contact with the water used at the time of ingestion and the saliva in the oral cavity to bring the granules into a resilient and plastic state, and the granules are unnecessary.
  • the components used in the present invention that become a viscous liquid when water is added include those that become partially or wholly viscous when 0.1 mg to 10 g are added to 1 mL of water.
  • the content in the granules of the present invention is preferably 0.01% to 95%, more preferably 0.1% to 50%.
  • the granules of the present invention may be granules containing a soluble additive as an excipient.
  • the soluble additive is an additive which is soluble in water and has a property of binding particles by physical or electrostatic action, and specific examples thereof include sugars, sugar alcohols, and amino acids. And derivatives thereof, polyols such as polyethylene glycol, solubilized cellulose derivatives, and soluble epoxy or acrylic polymers.
  • the soluble acryl polymer in the examples of the soluble additive means a polymer in which an acrylic acid derivative and / or a methacrylic acid derivative is polymerized and is soluble.
  • sugars and sugar alcohols having preferably less than 24 carbon atoms are mentioned, more preferably mannitol, xylitol, sorbitol, erythritol and trehalose.
  • sugars and sugar alcohols having preferably less than 24 carbon atoms are mentioned, more preferably mannitol, xylitol, sorbitol, erythritol and trehalose.
  • the active ingredient, excipient or active ingredient which does not dissolve or disintegrate sufficiently even if it contains a component which becomes a viscous liquid when water is added according to the present invention, although it is easy to prepare granules that Is coated or matrixed with one or more coating agents selected from the group consisting of acrylic polymers, cellulose polymers, natural polymers, fats and oils, fats and oils, etc. Even in the case of granules containing the active ingredient that has become soluble, the ingestion can be improved to a higher degree without causing a feeling of roughness.
  • the strength of the granules is increased by the binding force of the components that become a viscous liquid when water is added, and when a disintegrant that becomes a viscous liquid when water is used, Faster dissolution or disintegration rate.
  • a soluble additive a powder or crystal having an average particle size of less than 50 zm, or a powder or crystal having an average particle size of less than 50 zm collected as primary particles, and having a mean particle size of 30 to 500 m.
  • a soluble additive in one of the following particle forms is used, its ingestibility is better, but the powder or crystal form has an average particle diameter of 50 m or more, and the powder or crystal has a mean particle diameter of less than 50 m.
  • the soluble additive is in the form of secondary particles having an average particle diameter of 500 zm or more, which are collected as primary particles, the ingestibility is good. Further, the soluble additive has an effect of rapidly dissolving or swelling a component which becomes a viscous liquid when water is added, and this combination is more preferable.
  • the granules of the present invention may contain various additives used for the production of general preparations, and the amount of addition may be the amount used for production of general preparations.
  • additives include sour agents, foaming agents, artificial sweeteners, flavors, lubricants, coloring agents, stabilizers, and solubilizers.
  • sour agent examples include cunic acid, tartaric acid, malic acid and the like.
  • foaming agent examples include baking soda and the like.
  • Artificial sweeteners include, for example, sodium saccharin, glycyrrhizin double-strength lime, aspartame, stevia,
  • the flavor include lemon, lemon lime, orange, beriichi stoguchi, vanilla, and menthol.
  • the lubricant include magnesium stearate, sucrose fatty acid ester, polyethylene glycol, talc, stearic acid and the like.
  • Coloring agents include, for example, food colors such as Food Yellow No. 5, Food Red No. 2, Food Blue No. 2, etc. Gala and the like.
  • the stabilizer include antioxidants such as tocopherol and sodium sulfite, basic substances when the active ingredient is basic, and acidic substances when the active ingredient is acidic.
  • the solubilizer include cyclodextrin, polysorbate, and sodium lauryl sulfate.
  • the granules of the present invention can be produced by any of the methods generally used in the production of granules, such as fluidized bed granulation, stirring granulation, tumbling granulation, tumbling fluidized bed granulation, and extrusion granulation. I just need.
  • a component that is hardly soluble in water or a sleeping liquid a component that becomes a viscous liquid when water is added, and other components as necessary, and mix well.
  • granulate using purified water, ethanol, etc.
  • stirring granulation, tumbling granulation, tumbling fluidized bed granulation, extrusion granulation, etc. add the required amount of purified water, ethanol, etc. to the desired size.
  • Granulate At this time, purified water, ethanol and the like may be added together with the binder. After granulation, it is dried by a commonly used method.
  • Granules can be obtained by classifying the dried granules with a desired sieve or the like. At this time, the pills, granules, fine granules and powders described in the Japanese Pharmacopoeia can be obtained by adjusting the aperture of the sieve. An antistatic agent or a flavoring / flavoring agent may be added to the obtained granules. It may be filled in a bottle or packed as a package.
  • the granules thus obtained may be compression-molded with a tableting machine to produce tablets.
  • the strength of the granules is evaluated from the particle generation rate (%) when 1 g of the granules is placed in a test tube with a diameter of 15 mm and shaken up and down at 40 mm and shaken 300 times per minute for 60 minutes. Conducted a disintegration test according to the Japanese Pharmacopoeia13, and evaluated from the average disintegration time (sec).
  • the granules of the present invention had sufficient strength and good disintegration properties, and were granules that were free of roughness and easy to take. ⁇ available

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des granulés de grosseur réduite pour un dosage dans la cavité orale, caractérisés en ce qu'ils contiennent un composant peu soluble dans l'eau ou dans la salive, et un composant transformé en un liquide visqueux après addition d'eau.
PCT/JP2002/009910 2001-09-26 2002-09-26 Granules presentant des proprietes de dosage ameliorees WO2003026619A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003530256A JPWO2003026619A1 (ja) 2001-09-26 2002-09-26 服用性が改善された顆粒

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001-295143 2001-09-26
JP2001295143 2001-09-26

Publications (1)

Publication Number Publication Date
WO2003026619A1 true WO2003026619A1 (fr) 2003-04-03

Family

ID=19116627

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/009910 WO2003026619A1 (fr) 2001-09-26 2002-09-26 Granules presentant des proprietes de dosage ameliorees

Country Status (2)

Country Link
JP (1) JPWO2003026619A1 (fr)
WO (1) WO2003026619A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009474A1 (fr) * 2003-07-24 2005-02-03 Shionogi & Co., Ltd. Agent pharmaceutique sec pour sirop, difficilement soluble dans l'eau
JP2009520704A (ja) * 2005-12-21 2009-05-28 エーディーディー アドバンスト ドラッグ デリバリー テクノロジーズ リミテッド 水溶性担体を持つコアを含むペレット
WO2012173226A1 (fr) * 2011-06-17 2012-12-20 株式会社 三和化学研究所 Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique
JP2013075864A (ja) * 2011-09-30 2013-04-25 House Foods Corp 顆粒
WO2019202968A1 (fr) 2018-04-17 2019-10-24 株式会社ダイセル Préparation ganulaire facile à prendre et procédé pour sa production

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198761A (ja) * 1995-01-24 1996-08-06 Hokuriku Seiyaku Co Ltd ポリカルボフィルカルシウム含有製剤
JPH11130662A (ja) * 1997-08-29 1999-05-18 Toyama Chem Co Ltd 速崩壊性固形製剤
EP0976408A1 (fr) * 1998-07-31 2000-02-02 Nikken Chemicals Company, Limited Préparation à base de résine échangeuse de cations contenant un gélifiant
JP2000336025A (ja) * 1999-05-28 2000-12-05 Kureha Chem Ind Co Ltd カワラタケ由来の蛋白多糖体のコーティング粒状製剤
JP2001114703A (ja) * 1999-10-13 2001-04-24 Shin Etsu Chem Co Ltd 固形製剤とその製造方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08198761A (ja) * 1995-01-24 1996-08-06 Hokuriku Seiyaku Co Ltd ポリカルボフィルカルシウム含有製剤
JPH11130662A (ja) * 1997-08-29 1999-05-18 Toyama Chem Co Ltd 速崩壊性固形製剤
EP0976408A1 (fr) * 1998-07-31 2000-02-02 Nikken Chemicals Company, Limited Préparation à base de résine échangeuse de cations contenant un gélifiant
JP2000336025A (ja) * 1999-05-28 2000-12-05 Kureha Chem Ind Co Ltd カワラタケ由来の蛋白多糖体のコーティング粒状製剤
JP2001114703A (ja) * 1999-10-13 2001-04-24 Shin Etsu Chem Co Ltd 固形製剤とその製造方法

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009474A1 (fr) * 2003-07-24 2005-02-03 Shionogi & Co., Ltd. Agent pharmaceutique sec pour sirop, difficilement soluble dans l'eau
JPWO2005009474A1 (ja) * 2003-07-24 2006-11-09 塩野義製薬株式会社 難水溶性薬物を含むドライシロップ剤
JP2009520704A (ja) * 2005-12-21 2009-05-28 エーディーディー アドバンスト ドラッグ デリバリー テクノロジーズ リミテッド 水溶性担体を持つコアを含むペレット
WO2012173226A1 (fr) * 2011-06-17 2012-12-20 株式会社 三和化学研究所 Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique
JP2013075864A (ja) * 2011-09-30 2013-04-25 House Foods Corp 顆粒
WO2019202968A1 (fr) 2018-04-17 2019-10-24 株式会社ダイセル Préparation ganulaire facile à prendre et procédé pour sa production
CN111936168A (zh) * 2018-04-17 2020-11-13 株式会社大赛璐 易服用性颗粒剂及其制造方法
KR20210002478A (ko) 2018-04-17 2021-01-08 주식회사 다이셀 복용 용이성 과립제 및 그 제조 방법
JPWO2019202968A1 (ja) * 2018-04-17 2021-04-22 株式会社ダイセル 易服用性顆粒剤及びその製造方法

Also Published As

Publication number Publication date
JPWO2003026619A1 (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
JP6325627B2 (ja) 口腔内崩壊錠及びその製造方法
RU2189227C2 (ru) Быстро распадающиеся прессованные в формах материалы и способ их получения
ES2429689T3 (es) Tableta y polvo granulado que contienen 6-fluoro-3-hidroxi-2-pirazinocarboxamida
JP5366233B2 (ja) 口腔内崩壊錠剤
WO2001072285A1 (fr) Granule facile a prendre
JP3996626B2 (ja) 口腔内速崩壊錠
JP6133445B2 (ja) 口腔内速崩壊性固形製剤用組成物
JP2010270019A (ja) 固形内服薬組成物
JP2016174616A (ja) 崩壊性組成物及び易崩壊性圧縮成型物
JP2003176242A (ja) 速崩壊性圧縮成型物及びその製造法
WO2003026619A1 (fr) Granules presentant des proprietes de dosage ameliorees
JP6262490B2 (ja) 口腔内速崩壊性錠剤用組成物
JP6092672B2 (ja) 口腔内速崩壊性錠剤
WO2011049122A1 (fr) Comprimé de pravastatine sodique à désintégration rapide dans la cavité orale et son procédé de fabrication
JP2005139086A (ja) 速崩壊製剤
JP2011057655A (ja) 口腔内崩壊錠
JP2002138055A (ja) 口腔内速崩壊性圧縮成型物およびその製造方法
Patel et al. Formulation design and optimization of tastemasked mouth-dissolving tablets of Tramadol hydrochloride
JP2005298338A (ja) 速崩壊性圧縮成形製剤
JP6438547B2 (ja) 口腔内速崩壊性錠剤用組成物
US20240091367A1 (en) Orally disintegrating palatable formulations of drotaverine and method of preparation thereof
JP5502358B2 (ja) 口腔内速崩壊性錠剤およびその製造方法
JP2004107258A (ja) 催眠用圧縮成型製剤
WO2002092058A1 (fr) Preparation solide se desintegrant rapidement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003530256

Country of ref document: JP

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase